(NASDAQ: INDV) Indivior's forecast annual revenue growth rate of 0.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 134.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Indivior's revenue in 2025 is $1,181,000,000.On average, 9 Wall Street analysts forecast INDV's revenue for 2025 to be $150,199,238,091, with the lowest INDV revenue forecast at $137,214,432,803, and the highest INDV revenue forecast at $156,691,640,735. On average, 9 Wall Street analysts forecast INDV's revenue for 2026 to be $143,207,419,859, with the lowest INDV revenue forecast at $126,601,851,558, and the highest INDV revenue forecast at $157,565,618,014.
In 2027, INDV is forecast to generate $151,447,777,061 in revenue, with the lowest revenue forecast at $135,965,893,833 and the highest revenue forecast at $166,430,244,701.